Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous labetalol versus hydralazine for severe hypertension in pregnancy
PACTR202010738538062Completed
- Sponsor
- MUHAMMAD Sagir
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in maternal hypertension (HDP) comparing Intravenous labetalol with Intravenous hydralazine (2 arms). Primary endpoints: Mean reduction in mean arterial blood pressure and Rate of persistent hypertension. Started Oct 2018; status: completed.
02
Drugs
labetalolhydralazine
03
Conditions
maternal hypertension (HDP)
Beyond the preview
Go deeper on PACTR202010738538062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202010738538062.